Methods Of Treating Hfpef Employing Dapagliflozin And Compositions Comprising The Same
Patent No. EP3823631 (titled "Methods Of Treating Hfpef Employing Dapagliflozin And Compositions Comprising The Same") was filed by Astrazeneca on Jul 18, 2019. The application was issued on May 20, 2026.
Patent Summary
A pharmaceutical composition comprising a compound of Formula (I) or its prodrugs is provided for the treatment and prevention of heart failure with preserved ejection fraction (HFpEF) in non-diabetic human patients. The composition may be administered alone or in combination with other therapeutic agents, including antidiabetic agents (e.g., metformin, saxagliptin, biguanides, DPP4 inhibitors), anti-obesity, anti-hyperlipidemic, anti-hypertensive, anti-platelet, antithrombotic, anticoagulant agents, PPAR $\alpha/\delta$ agonists, FXR agonists, or anorectic agents (e.g., phenylpropanolamine, mazindol). Target patients typically exhibit symptomatic heart failure (NYHA class II-IV), LVEF >40%, and specific NT-proBNP thresholds ($\ge$300 pg/ml without or $\ge$600 pg/ml with atrial fibrillation/flutter). The composition may be formulated as a solid or sterile injectable.
Patent Family
Patent Oppositions (3)
Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.
Dossier Documents
The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.
Date
Description
Get instant alerts for new documents
EP3823631
- Application Number
- EP19759294A
- Filing Date
- Jul 18, 2019
- Status
- Granted And Under Opposition
- Apr 17, 2026
- Publication Date
- May 20, 2026
- External Links
- Slate, Register , Google Patents